Company Overview and News

42
Trade of the Day: CME Group Inc (CME)

2018-06-15 investorplace
To receive further updates on this CME Group Inc (NASDAQ:CME) trade as well as an alert when it’s time to take profits, sign up for a risk-free trial of Power Options Weekly today.
NDAQ 7018 CME

40
PFM: You May Want To Sell

2018-06-15 seekingalpha
With the Fed raising its key interest rate, it is a reminder we have to be very selective with what dividend funds we choose.
VIG 7018 CME

107
The EU Is Emerging as the New Sheriff for Global Financial Markets - Bloomberg

2018-06-15 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
FB 7018 CME MSFT

60
CME Group (CME) Prices $1.2 Billion Senior Unsecured Notes

2018-06-15 zacks
CME Group (CME - Free Report) recently announced the pricing of $1.2 billion senior notes. The notes will be issued in two tranches, 3.75% $500 million senior unsecured notes due 2028 and 4.15% $700 million senior unsecured notes due 2048. The company intends to deploy the proceeds from this offering along with cash in hand to finance the cash consideration of NEX Group plc by CME Group and CME London Limited.
SPG.PRJ 7018 CME CNA SPG NEXGY AB

40
Crypto coins surge after US regulator says they aren’t subject to securities rules

2018-06-15 scmp
Crypto enthusiasts have long worried that the SEC would crack down on Ether, which was originally offered in 2014 by the Ethereum Foundation, a Swiss nonprofit.
7018 CME

40
Bitcoin will be impossible to reflate into a bubble again - MarketWatch

2018-06-14 marketwatch
Also, with the Federal Reserve’s quantitative-tightening operations, there’s the potential for a much bigger dollar spike
7018 CME

40
Novogratz Firm Makes $15 Million Investment in Crypto Startup - Bloomberg

2018-06-14 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
7018 CME

40
Crypto Coins Surge as SEC Spares Ether From Securities Rules - Bloomberg

2018-06-14 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
7018 CME

40
Fed lifts rates as inflation picks up, drops crisis-era guidance

2018-06-14 bworldonline
WASHINGTON — The Federal Reserve raised interest rates on Wednesday, a move that was widely expected but still marked a milestone in the US central bank’s shift from policies used to battle the 2007-2009 financial crisis and recession.
7018 CME

40
Multimedia Weekly Digest: FOMC Hikes Again

2018-06-14 seekingalpha
Every week, we compile some of the best podcasts and videos our authors have to offer.
7018 CME

40
Fed lifts interest rates amid stronger inflation, drops crisis-era guidance

2018-06-14 thehindubusinessline
The Federal Reserve had raised interest rates on Wednesday, a move that was widely expected but still marked a milestone in the US central bank's shift from policies used to battle the 2007-2009 financial crisis and recession.
OBZIY OBEROIRLTY 7018 CME 533273

40
Fed lifts rates amid stronger inflation, drops crisis-era guidance

2018-06-13 malaymail
WASHINGTON, June 14 — The Federal Reserve raised interest rates on yesterday, a move that was widely expected but still marked a milestone in the US central bank's shift from policies used to battle the 2007-2009 financial crisis and recession.
7018 CME

40
Fed lifts rates amid stronger inflation, drops crisis-era guidance

2018-06-13 channelnewsasia
The Federal Reserve raised interest rates on Wednesday, a move that was widely expected but still marked a milestone in the U.S. central bank's shift from policies used to battle the 2007-2009 financial crisis and recession.
7018 CME

40
Fed raises rates amid stronger inflation, drops crisis-era guidance - Channel NewsAsia

2018-06-13 channelnewsasia
The Federal Reserve raised interest rates on Wednesday, a move that was widely expected but still marked a milestone in the U.S. central bank's shift from policies used to battle the 2007-2009 financial crisis and recession.
7018 CME

40
Fed raises rates amid stronger inflation, drops crisis-era guidance

2018-06-13 reuters
WASHINGTON (Reuters) - The Federal Reserve raised interest rates on Wednesday, a move that was widely expected but still marked a milestone in the U.S. central bank’s shift from policies used to battle the 2007-2009 financial crisis and recession.
7018 CME

Related Articles

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

3h - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

PRTO: Proteon Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...

GALE: Galena Biopharma Analysis and Research Report

2018-06-11 - Asif

Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...